Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The study is a 44 weeks, prospective, randomized, placebo-controlled, double-blinded,
parallel group two-center trial. Forty patients are recruited among the outpatients of the
chronic obstructive pulmonary disease (COPD) clinic, Hospital of South West Jutland and
Lillebælt Hospital according to the inclusion and exclusion criteria. The patients are
randomized to receive liraglutide 3 mg per day (initial dose 0.6 mg, increasing by 0.6 mg
weekly until 3 mg is reached) or placebo. At baseline, after four weeks (assessment of the
acute effect of liraglutide), 20 weeks, and 40 weeks (assessment of the combined effect of
liraglutide and weight loss) and at week 44 (assessment of the weight-loss after
discontinuation of liraglutide) the patients are assessed by physical examination, carbon
monoxide (CO) diffusion test, pulmonary function test, biomarkers of inflammation (CRP,
interleucine-6 (IL-6), monocyte chemitactic protein-1 (MCP-1)), Fluorodeoxyglucose
(FDG)/PET-CT scan of the lungs, 6-minute walking test, respiratory polygraphy and validated
questionnaires including basic dyspnea index, transition dyspnea index, COPD Assessment Test
(CAT)-score, short-form-36 (SF-36) and Epworth Sleepiness Score.